Abstract
ABSTRACTThe manufacture of biological products from live systems such as bacteria, mammalian, or insect cells is called biomanufacturing. The use of live cells introduces several operational challenges including batch-to-batch variability, parallel growth of both desired antibodies and unwanted toxic byproducts in the same batch, and random shocks leading to multiple competing failure processes. In this article, we develop a stochastic model that integrates the cell-level dynamics of biological processes with operational dynamics to identify optimal harvesting policies that balance the risks of batch failures and yield/quality tradeoffs in fermentation operations. We develop an infinite horizon, discrete-time Markov decision model to derive the structural properties of the optimal harvesting policies. We use IgG1 antibody production as an example to demonstrate the optimal harvesting policy and compare its performance against harvesting policies used in practice. We leverage insights from the optimal policy to propose smart stationary policies that are easier to implement in practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.